| Type | Public |
|---|---|
| Traded as | BSE: 500302 NSE: PIRHEALTH |
| Industry | Pharmaceuticals |
| Founded | 1988 |
| Headquarters | Mumbai, Maharashtra, India |
| Key people | Mr. Ajay Piramal, Dr. Swati Piramal |
| Products | Lacto Calamine – skin care range, Saridon – analgesic, Polycrol– digestive, Supractive Complete – a nutritional supplement, i-Pill – emergency contraceptive pill and Itchmasol – anti itching cream, Critical Care Products |
| Revenue | 3,671.05 crore (US$697.5 million) (2010)[1] |
| Net income | 481.74 crore (US$91.53 million) (2010) |
| Website | piramalhealthcare.com |
Piramal Healthcare is an Indian Pharmaceutical and Contract Research company, Headquartered in Mumbai, with its clinical research operations division, Piramal Clinical Research offices in Mumbai, Hyderabad and Bangalore.[2]
Since its inception, Piramal has differentiated itself among Indian pharmaceutical companies by consistently respecting global intellectual property rights and partnering innovator pharmaceutical companies. The Company has products, technology and manufacturing partnerships with leading global innovator pharmaceutical companies. With assets across North America, Europe and Asia, Piramal Healthcare is also one of the largest custom manufacturing companies across the World.
Contents |
1. Pharma Solutions (Custom Manufacturing for innovator companies) 2. Piramal Critical Care (Inhalation anaesthesia gases business) 3. Over the Counter (OTC) 4. Innovative discovery & commercialization
This is a global business that caters to drug requirement of hospitals worldwide. PHL has presence in 100+ countries globally either through distributors or through own office. PHL has a global R&D division in Orchard Park, NY, a facility in Digwal, India, and a manufacturing plant in Bethlehem, PA. This division had sales of 3.9 billion in FY11.
This is a domestic business that caters to Indian consumers through sales of OTC products. We have a strong product portfolio such as Lacto Calamine – skin care range, Saridon – analgesic, Polycrol– digestive, Supractive Complete – a nutritional supplement, i-Pill – emergency contraceptive pill and Itchmasol – anti itching cream.
The Board of PHL has approved the scheme of De-merger of the New Chemical Entity (NCE) Research Unit of Piramal Life Sciences Limited (PLSL) into Piramal Healthcare Limited. Under the proposed De-merger scheme, each shareholder of PLSL will be entitled to one fully paid up equity share of Rs. 2 each of PHL for every four equity shares of Rs. 10 each held in PLSL. Since April 2007, when PLSL was de-merged from PHL as an independent discovery research company, it has made significant progress. The pipeline of R&D programs has increased from nine to twenty four with nine additional programs moving into Phase I/II clinical trials and two additional program moving into Phase II clinical trials. Subsequent to the significant progress that PLSL has made, the risk profile of NCE R&D activity has reduced considerably.
Allergan India Private Limited
Allergan India is the leader in the Indian ophthalmology space. It plays a pioneering role in developing the ophthalmology marketing the country through its marketing programs and services. Allergan’s major initiatives for the India market include improving awareness, diagnosis and treatment of glaucoma, developing the treatment of ocular surface disease/ dry eye, and introducing new surgical products, particularly in small incision cataract surgery, where it is market leader. The Company achieved a turnover of Rs. 1.4 billion in FY2011. [3]